Cardiovascular Benefits of Spironolactone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from a Win Ratio Analysis of the TOPCAT Trial
This post hoc analysis, using a novel statistical approach, demonstrates the consistent benefits of spironolactone across adverse cardiovascular events, patient symptoms, functional status and quality of life in individuals with HF and mildly reduced or preserved LVEF.
Authors
- Nguyễn Việt Dũng (ORCID: https://orcid.org/0000-0002-7487-219X)
- Hoai Thi Thu Nguyen (ORCID: https://orcid.org/0000-0003-1742-3061)
Institutions
- Bạch Mai Hospital (VN)
Publication Details
- Journal
- Cardiac failure review
- Published
- 2025-10-14
- DOI
- https://doi.org/10.15420/cfr.2025.28
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00